An official website of the United States government
NIH Websites Are Changing Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Trial Status: active
This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with
pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical
cancer.
Inclusion Criteria
Age 18 years and older.
Recurrent or metastatic cervical cancer (histologically or cytologically confirmed)
Must have been treated with pembrolizumab, either as monotherapy or in combination, for atleast 6 weeks.
Subjects must have histologically or cytologically confirmed HPV positive disease
Measurable disease that can be accurately measured by RECIST v1.1 criteria
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy ≥ 12 weeks from the time of enrollment.
Must have adequate organ function
Negative serum pregnancy test. Women of child-bearing potential (WOCBP) must agree to use adequate contraception prior to study entry and for at least 6 months following completion of study treatment.
All patients must have the ability to understand and willingness to sign a written informed consent.
Exclusion Criteria
Prior chemotherapy, targeted therapy within 14 days; monoclonal antibody within 4 weeks; unresolved AEs.
Immunodeficiency, active autoimmune disease on immunosuppression, or immunosuppressive therapy within 7 days. HIV eligible with disease control.
Active hepatitis B (HBsAg+) or hepatitis C (HCV RT-PCR+) within 30 days of enrollment.
History of non-infectious pneumonitis or interstitial lung disease.
History of endocrine autoimmune disease (exceptions: treated Graves' disease; hypothyroidism on replacement).
Live vaccine within 30 days prior to first dose.
Patients with presence of other active malignancy within 1 year prior to study entry
Known Central Nervous System (CNS) disease
Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
Known history of active tuberculosis (TB, Bacillus tuberculosis).
Pregnant and lactating women are excluded from this study.
Patients with a history of solid organ transplant.
Patients currently participating in a study of an investigational agent or have used an investigational device within 4 weeks prior to the first dose of study treatment.
Patients, who in the opinion of the investigator, may not be able to comply with the monitoring requirements of the study.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06157151.